Background The coronavirus disease 2019 (COVID-19) pandemic has caused recurring and major outbreaks in multiple human populations around the world. The plethora of clinical presentations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been described extensively, of which olfactory dysfunction (OD) was established as an important and common extrapulmonary manifestation of COVID-19 infection. The aim of this protocol is to conduct a systematic review and meta-analysis on peer-reviewed articles which described clinical data of OD in COVID-19 patients.
Methods This research protocol has been prospectively registered with the Prospective Register of Systematic Reviews (PROSPERO; CRD42020196202). CINAHL, ClinicalTrials.gov, Cochrane Central, EMBASE, MEDLINE and PubMed, as well as Chinese medical databases: China National Knowledge Infrastructure (CNKI), VIP and WANFANG will be searched using keywords including “COVID-19”, “coronavirus disease”, “2019-nCoV”, “SARS-CoV-2”, “novel coronavirus”, “anosmia”, “hyposmia”, “loss of smell”, and “olfactory dysfunction”. Systematic review and meta-analysis will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Meta-analyses Of Observational Studies in Epidemiology (MOOSE) guidelines. Articles will be screened according to pre-specified inclusion and exclusion criteria to extract studies that include new clinical data investigating the effect of COVID-19 on olfactory dysfunction. Included articles will be reviewed in full; data including patient demographics, clinical characteristics of COVID-19-related OD, methods of olfactory assessment, and relevant clinical outcomes will be extracted. Statistical analyses will be performed using the Comprehensive Meta-Analysis version 3.
Discussion This systematic review and meta-analysis protocol will aim to collate and synthesise all available clinical evidence regarding COVID-19-related OD as an important neurosensory dysfunction of COVID-19 infection. A comprehensive search strategy and screening process will be conducted to incorporate broad clinical data for robust statistical analyses and representation. The outcome of the systematic review and meta-analysis will aim to improve our understanding of the symptomatology and clinical characteristics of COVID-19-related OD and identify knowledge gaps in its disease process, which will guide future research in this specific neurosensory defect.
Systematic Review registration: PROSPERO registration number: CRD42020196202
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Posted 12 Feb, 2021
On 11 Mar, 2021
On 25 Feb, 2021
Received 15 Feb, 2021
On 07 Feb, 2021
Invitations sent on 07 Feb, 2021
On 06 Feb, 2021
On 06 Feb, 2021
On 06 Feb, 2021
On 13 Jan, 2021
Received 12 Jan, 2021
Received 09 Jan, 2021
On 04 Jan, 2021
On 04 Jan, 2021
Received 04 Jan, 2021
On 03 Jan, 2021
On 02 Jan, 2021
On 01 Jan, 2021
Invitations sent on 01 Jan, 2021
On 01 Jan, 2021
On 01 Jan, 2021
On 29 Nov, 2020
Received 21 Nov, 2020
Received 19 Nov, 2020
Received 19 Nov, 2020
On 14 Nov, 2020
Received 13 Nov, 2020
On 11 Nov, 2020
On 10 Nov, 2020
On 08 Nov, 2020
Received 07 Oct, 2020
On 29 Sep, 2020
Invitations sent on 27 Sep, 2020
On 13 Sep, 2020
On 12 Sep, 2020
On 12 Sep, 2020
On 12 Aug, 2020
On 27 Jul, 2020
On 26 Jul, 2020
On 21 Jul, 2020
On 21 Jul, 2020
Posted 12 Feb, 2021
On 11 Mar, 2021
On 25 Feb, 2021
Received 15 Feb, 2021
On 07 Feb, 2021
Invitations sent on 07 Feb, 2021
On 06 Feb, 2021
On 06 Feb, 2021
On 06 Feb, 2021
On 13 Jan, 2021
Received 12 Jan, 2021
Received 09 Jan, 2021
On 04 Jan, 2021
On 04 Jan, 2021
Received 04 Jan, 2021
On 03 Jan, 2021
On 02 Jan, 2021
On 01 Jan, 2021
Invitations sent on 01 Jan, 2021
On 01 Jan, 2021
On 01 Jan, 2021
On 29 Nov, 2020
Received 21 Nov, 2020
Received 19 Nov, 2020
Received 19 Nov, 2020
On 14 Nov, 2020
Received 13 Nov, 2020
On 11 Nov, 2020
On 10 Nov, 2020
On 08 Nov, 2020
Received 07 Oct, 2020
On 29 Sep, 2020
Invitations sent on 27 Sep, 2020
On 13 Sep, 2020
On 12 Sep, 2020
On 12 Sep, 2020
On 12 Aug, 2020
On 27 Jul, 2020
On 26 Jul, 2020
On 21 Jul, 2020
On 21 Jul, 2020
Background The coronavirus disease 2019 (COVID-19) pandemic has caused recurring and major outbreaks in multiple human populations around the world. The plethora of clinical presentations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been described extensively, of which olfactory dysfunction (OD) was established as an important and common extrapulmonary manifestation of COVID-19 infection. The aim of this protocol is to conduct a systematic review and meta-analysis on peer-reviewed articles which described clinical data of OD in COVID-19 patients.
Methods This research protocol has been prospectively registered with the Prospective Register of Systematic Reviews (PROSPERO; CRD42020196202). CINAHL, ClinicalTrials.gov, Cochrane Central, EMBASE, MEDLINE and PubMed, as well as Chinese medical databases: China National Knowledge Infrastructure (CNKI), VIP and WANFANG will be searched using keywords including “COVID-19”, “coronavirus disease”, “2019-nCoV”, “SARS-CoV-2”, “novel coronavirus”, “anosmia”, “hyposmia”, “loss of smell”, and “olfactory dysfunction”. Systematic review and meta-analysis will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Meta-analyses Of Observational Studies in Epidemiology (MOOSE) guidelines. Articles will be screened according to pre-specified inclusion and exclusion criteria to extract studies that include new clinical data investigating the effect of COVID-19 on olfactory dysfunction. Included articles will be reviewed in full; data including patient demographics, clinical characteristics of COVID-19-related OD, methods of olfactory assessment, and relevant clinical outcomes will be extracted. Statistical analyses will be performed using the Comprehensive Meta-Analysis version 3.
Discussion This systematic review and meta-analysis protocol will aim to collate and synthesise all available clinical evidence regarding COVID-19-related OD as an important neurosensory dysfunction of COVID-19 infection. A comprehensive search strategy and screening process will be conducted to incorporate broad clinical data for robust statistical analyses and representation. The outcome of the systematic review and meta-analysis will aim to improve our understanding of the symptomatology and clinical characteristics of COVID-19-related OD and identify knowledge gaps in its disease process, which will guide future research in this specific neurosensory defect.
Systematic Review registration: PROSPERO registration number: CRD42020196202
Figure 1
Loading...